Últimas noticias sobre Edesa Biotech (NASDAQ:EDSA) Bolsa

Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMOD

DGLY

EDSA

El Índice de Precios al Productor en EE. UU. subió un 3,5% en enero, superando las previsiones. ¿Cómo reaccionaron los mercados?

Acciones de EE. UU. reaccionan al alza tras el aumento del PPI: ¿qué esperar ahora?

Edesa Biotech Inc

CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) ("Onconetix" or the "Company") (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex.
Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late clinical stage ophthalmic assets will immediately expand our reach beyond oncology , enhancing shareholder value."
Anthony W. Amato, President, CEO of Ocuvex, commented, "With an already FDA approved product, and late stage clinical assets, we believe that combining with Onconetix will allow us to broaden access to capital while continuing to focus on innovation and customer satisfaction. This is an exciting new chapter for our employees, customers, and stakeholders."
Onconetix and Ocuvex will continue negotiations to enter into a definitive agreement. Upon closing of the proposed transaction, Onconetix will acquire all the issued and outstanding equity interests of Ocuvex in exchange for newly issued shares of common stock of Onconetix. Immediately following the closing of the proposed transaction, the pre-closing Ocuvex equity holders will own approximately 90% of the equity interests in Onconetix.&nbsp;&nbsp;
The Letter of Intent only represents a mutual indication of interest regarding the proposed transaction, and the terms of any such transaction are subject to a number of contingencies, including the completion of due diligence and the negotiation and execution of a definitive agreement. Completion of the proposed transaction will be subject to customary conditions, including (i) the completion of adequate financing, and (ii) the obtainment of applicable regulatory, stockholder and third-party approvals. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will completed as proposed, or at all.

Biotech

General

ONCO

Onconetix Signs Letter Of Intent Contemplating Business Combination With Ocuvex Therapeutics

Wells Fargo analyst Roger Read downgrades Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) from Overweight to Equal-Weight and lowers the price target from $20 to $11.

Downgrades

Price Target

Analyst Ratings

LBRT

Wells Fargo Downgrades Liberty Energy to Equal-Weight, Lowers Price Target to $11

WIIM

CVS Health shares are trading higher after the company announced changes to management and Medicare increased advantage payment rates.

Wells Fargo analyst Roger Read upgrades Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) from Equal-Weight to Overweight and lowers the price target from $46 to $44.

Upgrades

Wells Fargo Upgrades Schlumberger to Overweight, Lowers Price Target to $44

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) with a Buy and maintains $15 price target.

Reiteration

INZY

Needham Reiterates Buy on Inozyme Pharma, Maintains $15 Price Target

LUNR

Intuitive Machines Selects SpaceX's Falcon 9 Rocket To Launch Its IM-4 Mission From Florida

Market-Moving Exclusives

Exclusives

BLNE

EXCLUSIVE: Beeline Holdings Tells Benzinga 'Beeline's originations increased by $46M in 2024, up 38%—versus industry growth of 9%'

EXCLUSIVE: Beeline Holdings Tells Benzinga Co. Announces That Its 2024 Growth In Origination Volume Outpaced The Broader Industry By 29%

On Tuesday, fintech mortgage lender Beeline Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) reported that its 2024 origination volume growth outpaced the broader industry by 29%, clocking originations of just under $200 million.
According to the Mortgage Bankers Association (MBA), U.S. mortgage originations hit $1.79 trillion in 2024, marking a recovery from the 2022 downturn. Since the Q4 2022 low, Beeline has averaged nearly 20% quarterly revenue growth through Q4 2024, the company said.
Founded in the second half of 2020, Beeline closed its first full year in 2021 with $7.8 million in revenue. Despite rising interest rates and a prolonged mortgage downturn that began in October 2021, the company grew revenue by 33.5% in 2024 compared to 2023—defying broader industry declines.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44471561/exclusive-beeline-ceo-buys-stock-at-205-premium-in-series-g-offering" rel="noreferrer noopener">Beeline CEO Buys Stock At 205% Premium In Series G Offering</a>
Looking ahead, the MBA's baseline forecast projects 30-year mortgage rates to end 2025 at approximately 5.9%. Beeline sees this as a favorable backdrop and believes it is well-positioned for accelerated growth through 2027.
Beeline Co-founder and CEO Nick Liuzza reflected on the company's early challenges, noting they entered the market during a turbulent time.
"Our timing wasn't ideal, but we've built the company to withstand volatility," he said.
"We caught a favorable market to close out 2021, but like the rest of the industry, we were hit by rising rates and a shortage of single-family homes. The difference is—we didn't slow down. We kept building software, expanded our product suite, and diversified our lending capabilities. Now, we're positioned to move quickly. With rates coming down last week, our timing as a public company seems excellent."
Price Action: BLNE shares were trading lower by 1.21% by $1.63 in premarket trading at the last check on Tuesday.

Fintech news covering the emerging Financial Technology services sector

Fintech

EXCLUSIVE: Beeline Clocks About $200 Million Mortgage Origination Volume In 2024

Ten percent — that's how much the Nasdaq has dropped in just one week. The S&amp;P 500 is close behind, down 8.80%, with the Dow falling 7.60% over the same period.
With all this volatility — as the VIX hit a high of 45.60 — Bitcoin, as of April 4th, is up over 1% on the day.
Weird, right? When it comes to &#8216;risk-on&#8217; assets, Bitcoin has typically been viewed as the riskiest — but over the last few weeks, we've seen a correlation that's anything but typical.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Bitcoin&#8217;s Historical Behavior and Correlation with Other Asset Classes
From 2012 through 2023, Bitcoin was either the top or bottom performing asset in every calendar year — never in the middle — <a href="https://www.wisdomtree.com/investments/-/media/us-media-files/documents/resource-library/market-insights/gannatti-commentary/bitcoin-correlations.pdf">per WisdomTree&#8217;s March 2024 report</a>, "Dynamic Correlations: Bitcoin vs. Other Asset Classes." In nine of those years, it outperformed everything else. But in years like 2018 and 2022, it dropped over 60%, showing how extreme its swings can be.
What's even more interesting is Bitcoin's low and constantly shifting correlation to traditional assets. WisdomTree's data shows its 50-day rolling correlation to the S&amp;P 500 has typically ranged between -0.1 to 0.2, sometimes spiking, but never staying consistent. This suggests that Bitcoin isn't reliably tied to equities and can act differently in times of stress — exactly like what we're seeing now.
"The hardest single thing to understand about correlation is that it is always shifting." – WisdomTree, 2024
So while the broader markets are bleeding, Bitcoin's resilience today could be a glimpse into its evolving role — possibly as a diversifier when traditional assets move in tandem.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Bitcoin and the S&amp;P 500: Comparing 1-Year Performance Trends
When it comes to the past year&#8217;s performance as of Friday, Bitcoin is up roughly 25%, while the S&amp;P 500 is down 7%. This means that if you had bought Bitcoin a year ago today, you'd be up, while the opposite is true for the S&amp;P 500.
Source: Godel Terminal (BTC v SPX &#8211; Year % Change)
While this data is not complex and doesn't delve into a more in-depth technical view, it's important to understand. The common view would be to sell Bitcoin during these downturns, as it has been considered the riskiest asset out there, but this simple data set shows otherwise in recent times.
When comparing the weekly structure of Bitcoin to certain US indices, Bitcoin has a much stronger chart in terms of staying above key pivot points.
For example, indices like the S&amp;P, Nasdaq, and Dow are all below the election swing point, while Bitcoin is still trading above that price level.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="633" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08071212/IMG_6850-1024x633.png" alt="" class="wp-image-861683" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08071212/IMG_6850-1024x633.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08071212/IMG_6850-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08071212/IMG_6850-768x475.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08071212/IMG_6850-1536x949.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08071212/IMG_6850.png 1600w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Source: TradingView (User: NoticeTrades)
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
While this isn't a direct indicator of whether Bitcoin will ultimately hold up during the current uncertain environment, it could mark the beginning of a shift we haven't seen before.&nbsp;
Bitcoin&#8217;s ability to stay above key levels while traditional assets falter suggests that it may be gaining more traction as a potential hedge or safe haven. In a world where central banks and governments are increasingly pushing the boundaries of monetary policy, Bitcoin's fixed supply and decentralized nature could allow it to act as a store of value in ways that traditional assets cannot.
The Road Ahead for Bitcoin
Despite its reputation for volatility and risk, Bitcoin&#8217;s recent performance in the face of macroeconomic uncertainty challenges conventional thinking about digital assets. Historically seen as a speculative, high-risk investment, Bitcoin is showing signs of evolving into something more, possibly even a safe haven during turbulent times.&nbsp;
With its continued strength above key price levels and its non-correlated behavior relative to traditional assets like the S&amp;P 500, Bitcoin could be paving the way for a new era of digital asset investment. Whether or not it fully holds up under the pressure of ongoing market turbulence remains to be seen, but the data suggests that those who write it off as a risk asset may be overlooking its emerging role in modern finance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

Selling Bitcoin On Recession Fears: Why It's a Flawed Plan And How Bitcoin May Hold Up In The Digital Asset Era

Wells Fargo analyst Ike Boruchow downgrades Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) from Overweight to Equal-Weight and lowers the price target from $80 to $70.

Wells Fargo Downgrades Signet Jewelers to Equal-Weight, Lowers Price Target to $70

Editor's note: Levi's reported revenue excludes its Dockers business, now classified as a discontinued operation. On a comparable basis, the company beat revenue expectations.
Levi Strauss &amp; Co.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) released its first-quarter results after Monday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/04/b44673925/levi-strauss-co-reports-better-than-expected-first-quarter-2025-financial-results"> from the report. </a>
The Details: Levi Strauss &amp; Co. reported quarterly adjusted earnings of 38 cents per share, which beat the 28 cent analyst consensus estimate. 
Quarterly revenue of $1.5 billion appeared to miss the $1.54 billion consensus estimate, but Levi's reported revenue excludes approximately $67 million in sales from its Dockers business, which has been reclassified as a discontinued operation. On a comparable basis, Levi's revenue beat expectations.
Read Next: <a href="https://www.benzinga.com/25/04/44667862/oil-crashes-to-60-per-barrel-as-recession-fears-grow">Oil Crashes To $60 Per Barrel As Global Recession Fears Grow</a>
Operating margin&nbsp;was 12.5% compared to 0.04% in the same period last year. Adjusted EBIT margin&nbsp;increased 400 basis points to 13.4% from 9.4% last year on a reported basis primarily due to higher gross margin.
&#8220;We exceeded revenue and profitability expectations in Q1 marking a strong start to the year, another proof point that our transformation strategy is working,&#8221;&nbsp;said Michelle Gass, CEO of Levi Strauss &amp; Co.
&#8220;The Levi&#8217;s&nbsp;brand is stronger than ever, and we will continue to fuel this momentum through a robust product pipeline and by keeping the brand firmly at the center of culture across the globe. While we recognize that we are operating in an uncertain environment, our global footprint, strong margin structure, and agile supply chain position us to navigate the balance of the year and beyond,&#8221; Gass added. 
Outlook:&nbsp;Levi said its 2025&nbsp;guidance remains unchanged other than to reflect its Dockers business as a discontinued operation and does not reflect any impact from the recently announced tariffs. 
LEVI Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Levi Strauss shares were up 2.52% after hours at $13.84 on publication Monday.&nbsp;&nbsp;
Read More:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase">Trump Slaps 25% Tariffs On Autos: What It Means For Your Next Car Purchase</a>&nbsp;</li>
</ul>
Image: Shutterstock

After-Hours Center

Movers

LEVI

Levi Strauss Shares Rise After Q1 Results: Details (CORRECTED)

Needham analyst James Ricchiuti maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and lowers the price target from $34 to $28.

KRNT

Needham Maintains Buy on Kornit Digital, Lowers Price Target to $28

Wells Fargo analyst Ike Boruchow upgrades Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) from Equal-Weight to Overweight and lowers the price target from $275 to $240.

Wells Fargo Upgrades Ralph Lauren to Overweight, Lowers Price Target to $240

Wells Fargo analyst Alec Brondolo upgrades Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) from Underweight to Equal-Weight and raises the price target from $169 to $176.

Wells Fargo Upgrades Wix.com to Equal-Weight, Raises Price Target to $176

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and maintains $24 price target.

TRVI

Needham Reiterates Buy on Trevi Therapeutics, Maintains $24 Price Target

Standard Chartered on Tuesday forecasted that XRP&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) market capitalization will overtake Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) by the end of 2028, positioning XRP as the <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">second-largest non-stablecoin digital asset</a>.
What Happened: The bold prediction, made by Geoffrey Kendrick, head of digital assets research at Standard Chartered, highlights XRP's growing role in cross-border payments amid shifting market dynamics.
The announcement coincides with the New York Stock Exchange's approval of a new leveraged XRP exchange-traded fund, signaling increased mainstream interest in the cryptocurrency.
In a note shared with Benzinga, Kendrick emphasized XRP's potential to outpace Ethereum over the next few years.
"By the end of 2028 we see XRP's market cap overtaking Ethereum's," he wrote, attributing the shift to XRP's core utility as a platform for cross-border and cross-currency payments. 
He noted that this segment of the digital asset market is experiencing a sustained increase in transaction volumes, a trend Standard Chartered expects to persist, bolstering XRP's value proposition.
Kendrick's analysis positions XRP alongside Bitcoin and Avalanche as top performers in the digital asset space, while identifying Ethereum as a relative underperformer. 
"XRP's core use is as a cross-border and cross-currency payments platform," Kendrick stated, underscoring its practical application as a key driver of its projected growth. 
He added that Bitcoin's resilience during recent market turbulence, including global tariff concerns, suggests a broader upward trajectory for cryptocurrencies, with XRP poised to benefit significantly.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44681738/bitcoin-is-a-more-liquid-and-higher-volatility-version-of-gold-bernstein">Bitcoin Is A &#8216;More Liquid And Higher Volatility Version Of Gold&#8217;: Bernstein</a>
Why It Matters: The prediction comes as XRP gains traction in traditional financial markets.
The NYSE approved the Teucrium 2x Long Daily XRP ETF (XXRP), set to launch on April 8.
This leveraged ETF, designed to deliver twice XRP's daily price performance through swap contracts, marks a milestone as the first XRP-tied ETF in the U.S. 
Unlike spot ETFs, it does not hold XRP directly but tracks its daily movements, offering investors an alternative entry point into the asset's price action. 
Following the news, XRP's price rose approximately 11%, reaching $1.96, according to Coingecko data.
Kendrick urged investors to remain focused on long-term opportunities despite short-term volatility. "Keep looking for winners and HODLing those you already own. 
Tariff mess will be over soon, and Bitcoin's solid performance during the noise tells us a leg higher for the asset class will follow," he advised. 
The bank's outlook reflects confidence in XRP's ability to capitalize on its niche in facilitating efficient international transactions, a use case that sets it apart from Ethereum's broader focus on smart contracts and decentralized applications.
While no spot XRP ETF has been approved in the U.S., the Securities and Exchange Commission has acknowledged several filings this year, suggesting regulatory progress. 
Bloomberg ETF analyst Eric Balchunas said on the unusual nature of a leveraged ETF preceding a spot product, noting that it's a rare occurrence in the digital asset space. 
The XXRP fund carries an annual expense ratio of 1.85%, reflecting the costs of its derivative-based strategy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44672506/blackrock-ceo-larry-fink-warns-many-already-believe-the-us-is-in-a-recession">BlackRock CEO Larry Fink Warns &#8216;Many Already Believe The US Is In A Recession&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$XRP

XRP Will Overtake Ethereum By 2028: Standard Chartered

Wells Fargo analyst John Kilichowski upgrades Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) from Equal-Weight to Overweight and maintains the price target from $158 to $158.

WELL

Wells Fargo Upgrades Welltower to Overweight, Maintains Price Target to $158

Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) with a Buy and maintains $59 price target.

RVMD

Needham Reiterates Buy on Revolution Medicines, Maintains $59 Price Target

CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) on Tuesday named Brian Newman as executive vice president and chief financial officer designate, effective&nbsp;April 21.
He will succeed current chief financial officer Tom&nbsp;Cowhey, who will transition as a strategic advisor to president and chief executive officer&nbsp;David Joyner, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44680644/cvs-health-announces-chief-financial-officer-transition-plan-appoints-chief-medical-officer" rel="noreferrer noopener">effective&nbsp;May 12</a>.
Newman was most recently executive vice president and chief financial officer of United Parcel Service Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth's PBMs Amid Commissioner Shortage</a>
Before joining UPS, Newman spent 26 years with PepsiCo, where he held finance leadership roles across&nbsp;Europe,&nbsp;Asia, and North and&nbsp;South America. He also served as executive vice president for PepsiCo's global operations and chief strategy officer. Newman began his career as an investment banker at PaineWebber.
Amy Compton-Phillips, the company's new executive vice president and chief medical officer, effective&nbsp;May 19, will also report to David&nbsp;Joyner.
Dr. Compton-Phillips was most recently chief physician executive of Press Ganey, a health care performance improvement company.
Prior to Press Ganey, Dr. Compton-Phillips was the president and chief clinical officer at Providence Health &amp; Services, a health care system, responsible for clinical operations and care including improving health, care, and value outcomes delivered by the system's hospitals, clinics, and caregivers. From 1985 to 2007, she held positions of increasing responsibility at Kaiser Permanente.
In February, CVS Health reported fourth-quarter sales of $97.71 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43709040/cvs-health-gains-momentum-after-q4-performance-analyst-upgrades-stock" rel="noreferrer noopener">consensus of $97.19 billion</a>.
Total revenues increased 4.2%, driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the&nbsp;Health Services segment.
The Medical benefit ratio increased from 88.5% to 94.8% compared to the prior year, driven by increased utilization, the unfavorable impact of the previously disclosed decline in the company's Medicare Advantage star ratings for the 2024 payment year, and the impact of higher acuity in Medicaid.
In October 2024, CVS Health&nbsp;appointed longtime executive&nbsp;David Joyner as its new president and CEO, replacing&nbsp;Karen Lynch amid the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">ongoing financial struggles</a>.
In November 2024, CVS&nbsp;Health appointed Prem&nbsp;Shah as the Group President, responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769048/cvs-health-announces-leadership-appointments" rel="noreferrer noopener">Healthcare Delivery businesses</a>.
In addition, the company appointed Steve Nelson&nbsp;as President of Aetna.
Price Action: At the last check on Tuesday, CVS stock was up 9.52% at $69.93 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/25/04/44680574/global-markets-rebound-in-relief-rally-gold-back-to-3000" target="_blank" rel="noreferrer noopener">Global Markets Rebound In Relief Rally, Gold Back To $3,000</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Management

CVS Health Appoints Former UPS And Pepsi Exec As Finance Chief, Stock Soars

Events

Press Releases

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Edesa Biotech Announces Upcoming Conference Schedule

Financing

Edesa Biotech's Founder Makes Strategic Investment in the Company

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces Chief Financial Officer Transition

HC Wainwright & Co.

Brookline Capital

Comments

Edesa Biotech

Noticias

Últimas noticias sobre Edesa Biotech (NASDAQ:EDSA) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL